Research

Endoceutics has five Phase III product candidates addressing large market opportunities and two Phase I/II product candidates and has exclusive worldwide rights to patents, patent applications, technology and know-how related to all its products.

Endoceutics drug pipeline

Endoceutics has five Phase III product candidates addressing large market opportunities and two Phase I/II product candidates and has exclusive worldwide rights to patents, patent applications, technology and know-how related to all its products.

Product
Indication
Pre-Clinical Phase I Phase II Phase III NDA
Intrarosa™ (Prasterone Intravaginal)
Vulvovaginal atropy
Approved US FDA - Nov 2016
Approved US FDA - Nov 2016
Prasterone (Intravaginal)
Sexual dysfunction
Phase III
ERC-242
Prasterone + Acolbifene (Oral)
Vasomotor symptoms
Phase III
ERC-249
Prasterone + Acolbifene (Prasterone)
Osteoporosis prevention
Phase III
Acolbifene
Breast cancer treament
Phase III
Acolbifene + Prasterone + GnRH agonist
Endometriosis
Phase III
Prasterone + Acolbifene
Male hypogonadism & Loss of libido
Phase III
Antiandrogens
Prostate cancer treatment
Phase I

Our research

A results-oriented approach and the implementation of effective solutions.

Intracrinology

The new science of sex steroid physiology after menopause, 500 million years in the making.

Intracrinology

Clinical Studies

It takes many years, many careful steps and a large number of participants to develop a safe and effective new therapy.

Our clinical studies